NAD-dependent deacetylase sirtuin 2 is an
enzyme that in humans is encoded by the SIRT2gene.[5][6][7] SIRT2 is an
NAD+ (nicotinamide adenine dinucleotide)-dependent deacetylase. Studies of this protein have often been divergent, highlighting the dependence of pleiotropic effects of SIRT2 on cellular context. The natural polyphenol
resveratrol is known to exert opposite actions on neural cells according to their normal or cancerous status.[8] Similar to other
sirtuin family members, SIRT2 displays a ubiquitous distribution. SIRT2 is expressed in a wide range of tissues and organs and has been detected particularly in metabolically relevant tissues, including the
brain,
muscle,
liver,
testes,
pancreas,
kidney, and
adipose tissue of mice. Of note, SIRT2 expression is much higher in the brain than all other organs studied, particularly in the
cortex,
striatum,
hippocampus, and
spinal cord.[9]
Function
Studies suggest that the human sirtuins may function as intracellular regulatory proteins with mono-ADP-ribosyltransferase activity.[7] Cytosolic functions of SIRT2 include the regulation of
microtubuleacetylation, control of
myelination in the
central and
peripheral nervous system[citation needed] and gluconeogenesis.[10] There is growing evidence for additional functions of SIRT2 in the
nucleus. During the
G2/M transition, nuclear SIRT2 is responsible for global
deacetylation of
H4K16, facilitating
H4K20methylation and subsequent
chromatin compaction.[11] In response to
DNA damage, SIRT2 was also found to deacetylate
H3K56 in vivo.[12] Finally, SIRT2 negatively regulates the
acetyltransferase activity of the transcriptional co-activator p300 via deacetylation of an automodification loop within its catalytic domain.[13]
Structure
Gene
Human SIRT2 gene has 18
exons resides on
chromosome 19 at q13.[7] For SIRT2, four different human splice variants are deposited in the GenBank sequence database.[14]
Protein
SIRT2 gene encodes a member of the
sirtuin family of proteins, homologs to the yeast Sir2 protein. Members of the sirtuin family are characterized by a sirtuin core domain and grouped into four classes. The protein encoded by this gene is included in class I of the sirtuin family. Several transcript variants are resulted from alternative splicing of this gene.[7] Only transcript variants 1 and 2 have confirmed protein products of physiological relevance. A
leucine-rich nuclear export signal (NES) within the
N-terminal region of these two isoforms is identified.[14] Since deletion of the NES led to nucleocytoplasmic distribution, it is suggested to mediate their cytosolic localization.[15]
(S)-2-Pentyl-6-chloro,8-bromo-chroman-4-one: IC50 of 1.5 μM, highly selective over SIRT2 and
SIRT3[17]
3′-Phenethyloxy-2-anilinobenzamide (33i): IC50 of 0.57 μM[18]
AGK2 (C23H13Cl2N3O2; 2-cyano-3-[5-(2,5-dichlorophenyl)-2-furanyl]-N-5-quinolinyl-2-propenamide) is a potent, cell-permeable, selective SIRT2 inhibitor that minimally affects both SIRT1 and SIRT3[19]
Animal studies
Metabolic actions
SIRT2 suppresses inflammatory responses in mice through
p65 deacetylation and inhibition of
NF-κB activity.[20] SIRT2 is responsible for the deacetylation and activation of
G6PD, stimulating
pentose phosphate pathway to supply cytosolic
NADPH to counteract oxidative damage and protect mouse
erythrocytes.[21]
Neurodegeneration
Several studies in cell and invertebrate models of
Parkinson's disease (PD) and
Huntington's disease (HD) suggested potential neuroprotective effects of SIRT2 inhibition, in striking contrast with other sirtuin family members.[22][23] In addition, recent evidence shows that inhibition of SIRT2 protects against
MPTP-induced neuronal loss in vivo.[24]
Clinical significance
Metabolic actions
Several SIRT2
deacetylation targets play important roles in metabolic
homeostasis. SIRT2 inhibits adipogenesis by deacetylating
FOXO1 and thus may protect against
insulin resistance. SIRT2 sensitizes cells to the action of insulin by physically interacting with and activating
Akt and downstream targets. SIRT2 mediates
mitochondrial biogenesis by deacetylating
PGC-1α, upregulates
antioxidant enzyme expression by deacetylating
FOXO3a, and thereby reduces
ROS levels.
Cell cycle regulation
Although preferentially cytosolic, SIRT2 transiently shuttles to the
nucleus during the G2/M transition of the
cell cycle, where it has a strong preference for
histone H4lysine 16 (
H4K16ac),[25] thereby regulating chromosomal condensation during
mitosis.[26] During the cell cycle, SIRT2 associates with several mitotic structures including the
centrosome,
mitotic spindle, and
midbody, presumably to ensure normal
cell division.[15] Finally, cells with SIRT2 overexpression exhibit marked prolongation of the cell cycle.[27]
Tumorigenesis
Mounting evidence implies a role for SIRT2 in
tumorigenesis. SIRT2 may suppress or promote tumor growth in a context-dependent manner. SIRT2 has been proposed to act as a tumor suppressor by preventing chromosomal instability during mitosis.[28] SIRT2-specific inhibitors exhibits broad anticancer activity.[29][30]
^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^Afshar G, Murnane JP (Jun 1999). "Characterization of a human gene with sequence homology to Saccharomyces cerevisiae SIR2". Gene. 234 (1): 161–68.
doi:
10.1016/S0378-1119(99)00162-6.
PMID10393250.
^Frye RA (Jun 1999). "Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity". Biochemical and Biophysical Research Communications. 260 (1): 273–79.
doi:
10.1006/bbrc.1999.0897.
PMID10381378.
^Suzuki T, Khan MN, Sawada H, Imai E, Itoh Y, Yamatsuta K, Tokuda N, Takeuchi J, Seko T, Nakagawa H, Miyata N (Jun 2012). "Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors". Journal of Medicinal Chemistry. 55 (12): 5760–73.
doi:
10.1021/jm3002108.
PMID22642300.
^Yang, W., Chen, W., Su, H., Li, R., Song, C., Wang, Z., & Yang, L. (2020). Recent advances in the development of histone deacylase SIRT2 inhibitors. RSC advances, 10(61), 37382-37390.
PMID35521274PMC9057128doi:
10.1039/d0ra06316a
^Gomes P, Outeiro TF, Cavadas C (Nov 2015). "Emerging Role of Sirtuin 2 in the Regulation of Mammalian Metabolism". Trends in Pharmacological Sciences. 36 (11): 756–68.
doi:
10.1016/j.tips.2015.08.001.
PMID26538315.
^Inoue T, Hiratsuka M, Osaki M, Yamada H, Kishimoto I, Yamaguchi S, Nakano S, Katoh M, Ito H, Oshimura M (Feb 2007). "SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress". Oncogene. 26 (7): 945–57.
doi:
10.1038/sj.onc.1209857.
PMID16909107.
S2CID21357335.
^Han Y, Jin YH, Kim YJ, Kang BY, Choi HJ, Kim DW, Yeo CY, Lee KY (Oct 2008). "Acetylation of Sirt2 by p300 attenuates its deacetylase activity". Biochemical and Biophysical Research Communications. 375 (4): 576–80.
doi:
10.1016/j.bbrc.2008.08.042.
PMID18722353.
^Jin YH, Kim YJ, Kim DW, Baek KH, Kang BY, Yeo CY, Lee KY (Apr 2008). "Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of p53". Biochemical and Biophysical Research Communications. 368 (3): 690–5.
doi:
10.1016/j.bbrc.2008.01.114.
PMID18249187.
Maruyama K, Sugano S (Jan 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–74.
doi:
10.1016/0378-1119(94)90802-8.
PMID8125298.
Andersson B, Wentland MA, Ricafrente JY, Liu W, Gibbs RA (Apr 1996). "A "double adaptor" method for improved shotgun library construction". Analytical Biochemistry. 236 (1): 107–13.
doi:
10.1006/abio.1996.0138.
PMID8619474.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (Oct 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56.
doi:
10.1016/S0378-1119(97)00411-3.
PMID9373149.
Frye RA (Jul 2000). "Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins". Biochemical and Biophysical Research Communications. 273 (2): 793–98.
doi:
10.1006/bbrc.2000.3000.
PMID10873683.
De Smet C, Nishimori H, Furnari FB, Bögler O, Huang HJ, Cavenee WK (May 2002). "A novel seven transmembrane receptor induced during the early steps of astrocyte differentiation identified by differential expression". Journal of Neurochemistry. 81 (3): 575–88.
doi:
10.1046/j.1471-4159.2002.00847.x.
PMID12065666.
S2CID23925334.
NAD-dependent deacetylase sirtuin 2 is an
enzyme that in humans is encoded by the SIRT2gene.[5][6][7] SIRT2 is an
NAD+ (nicotinamide adenine dinucleotide)-dependent deacetylase. Studies of this protein have often been divergent, highlighting the dependence of pleiotropic effects of SIRT2 on cellular context. The natural polyphenol
resveratrol is known to exert opposite actions on neural cells according to their normal or cancerous status.[8] Similar to other
sirtuin family members, SIRT2 displays a ubiquitous distribution. SIRT2 is expressed in a wide range of tissues and organs and has been detected particularly in metabolically relevant tissues, including the
brain,
muscle,
liver,
testes,
pancreas,
kidney, and
adipose tissue of mice. Of note, SIRT2 expression is much higher in the brain than all other organs studied, particularly in the
cortex,
striatum,
hippocampus, and
spinal cord.[9]
Function
Studies suggest that the human sirtuins may function as intracellular regulatory proteins with mono-ADP-ribosyltransferase activity.[7] Cytosolic functions of SIRT2 include the regulation of
microtubuleacetylation, control of
myelination in the
central and
peripheral nervous system[citation needed] and gluconeogenesis.[10] There is growing evidence for additional functions of SIRT2 in the
nucleus. During the
G2/M transition, nuclear SIRT2 is responsible for global
deacetylation of
H4K16, facilitating
H4K20methylation and subsequent
chromatin compaction.[11] In response to
DNA damage, SIRT2 was also found to deacetylate
H3K56 in vivo.[12] Finally, SIRT2 negatively regulates the
acetyltransferase activity of the transcriptional co-activator p300 via deacetylation of an automodification loop within its catalytic domain.[13]
Structure
Gene
Human SIRT2 gene has 18
exons resides on
chromosome 19 at q13.[7] For SIRT2, four different human splice variants are deposited in the GenBank sequence database.[14]
Protein
SIRT2 gene encodes a member of the
sirtuin family of proteins, homologs to the yeast Sir2 protein. Members of the sirtuin family are characterized by a sirtuin core domain and grouped into four classes. The protein encoded by this gene is included in class I of the sirtuin family. Several transcript variants are resulted from alternative splicing of this gene.[7] Only transcript variants 1 and 2 have confirmed protein products of physiological relevance. A
leucine-rich nuclear export signal (NES) within the
N-terminal region of these two isoforms is identified.[14] Since deletion of the NES led to nucleocytoplasmic distribution, it is suggested to mediate their cytosolic localization.[15]
(S)-2-Pentyl-6-chloro,8-bromo-chroman-4-one: IC50 of 1.5 μM, highly selective over SIRT2 and
SIRT3[17]
3′-Phenethyloxy-2-anilinobenzamide (33i): IC50 of 0.57 μM[18]
AGK2 (C23H13Cl2N3O2; 2-cyano-3-[5-(2,5-dichlorophenyl)-2-furanyl]-N-5-quinolinyl-2-propenamide) is a potent, cell-permeable, selective SIRT2 inhibitor that minimally affects both SIRT1 and SIRT3[19]
Animal studies
Metabolic actions
SIRT2 suppresses inflammatory responses in mice through
p65 deacetylation and inhibition of
NF-κB activity.[20] SIRT2 is responsible for the deacetylation and activation of
G6PD, stimulating
pentose phosphate pathway to supply cytosolic
NADPH to counteract oxidative damage and protect mouse
erythrocytes.[21]
Neurodegeneration
Several studies in cell and invertebrate models of
Parkinson's disease (PD) and
Huntington's disease (HD) suggested potential neuroprotective effects of SIRT2 inhibition, in striking contrast with other sirtuin family members.[22][23] In addition, recent evidence shows that inhibition of SIRT2 protects against
MPTP-induced neuronal loss in vivo.[24]
Clinical significance
Metabolic actions
Several SIRT2
deacetylation targets play important roles in metabolic
homeostasis. SIRT2 inhibits adipogenesis by deacetylating
FOXO1 and thus may protect against
insulin resistance. SIRT2 sensitizes cells to the action of insulin by physically interacting with and activating
Akt and downstream targets. SIRT2 mediates
mitochondrial biogenesis by deacetylating
PGC-1α, upregulates
antioxidant enzyme expression by deacetylating
FOXO3a, and thereby reduces
ROS levels.
Cell cycle regulation
Although preferentially cytosolic, SIRT2 transiently shuttles to the
nucleus during the G2/M transition of the
cell cycle, where it has a strong preference for
histone H4lysine 16 (
H4K16ac),[25] thereby regulating chromosomal condensation during
mitosis.[26] During the cell cycle, SIRT2 associates with several mitotic structures including the
centrosome,
mitotic spindle, and
midbody, presumably to ensure normal
cell division.[15] Finally, cells with SIRT2 overexpression exhibit marked prolongation of the cell cycle.[27]
Tumorigenesis
Mounting evidence implies a role for SIRT2 in
tumorigenesis. SIRT2 may suppress or promote tumor growth in a context-dependent manner. SIRT2 has been proposed to act as a tumor suppressor by preventing chromosomal instability during mitosis.[28] SIRT2-specific inhibitors exhibits broad anticancer activity.[29][30]
^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^Afshar G, Murnane JP (Jun 1999). "Characterization of a human gene with sequence homology to Saccharomyces cerevisiae SIR2". Gene. 234 (1): 161–68.
doi:
10.1016/S0378-1119(99)00162-6.
PMID10393250.
^Frye RA (Jun 1999). "Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity". Biochemical and Biophysical Research Communications. 260 (1): 273–79.
doi:
10.1006/bbrc.1999.0897.
PMID10381378.
^Suzuki T, Khan MN, Sawada H, Imai E, Itoh Y, Yamatsuta K, Tokuda N, Takeuchi J, Seko T, Nakagawa H, Miyata N (Jun 2012). "Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors". Journal of Medicinal Chemistry. 55 (12): 5760–73.
doi:
10.1021/jm3002108.
PMID22642300.
^Yang, W., Chen, W., Su, H., Li, R., Song, C., Wang, Z., & Yang, L. (2020). Recent advances in the development of histone deacylase SIRT2 inhibitors. RSC advances, 10(61), 37382-37390.
PMID35521274PMC9057128doi:
10.1039/d0ra06316a
^Gomes P, Outeiro TF, Cavadas C (Nov 2015). "Emerging Role of Sirtuin 2 in the Regulation of Mammalian Metabolism". Trends in Pharmacological Sciences. 36 (11): 756–68.
doi:
10.1016/j.tips.2015.08.001.
PMID26538315.
^Inoue T, Hiratsuka M, Osaki M, Yamada H, Kishimoto I, Yamaguchi S, Nakano S, Katoh M, Ito H, Oshimura M (Feb 2007). "SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress". Oncogene. 26 (7): 945–57.
doi:
10.1038/sj.onc.1209857.
PMID16909107.
S2CID21357335.
^Han Y, Jin YH, Kim YJ, Kang BY, Choi HJ, Kim DW, Yeo CY, Lee KY (Oct 2008). "Acetylation of Sirt2 by p300 attenuates its deacetylase activity". Biochemical and Biophysical Research Communications. 375 (4): 576–80.
doi:
10.1016/j.bbrc.2008.08.042.
PMID18722353.
^Jin YH, Kim YJ, Kim DW, Baek KH, Kang BY, Yeo CY, Lee KY (Apr 2008). "Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of p53". Biochemical and Biophysical Research Communications. 368 (3): 690–5.
doi:
10.1016/j.bbrc.2008.01.114.
PMID18249187.
Maruyama K, Sugano S (Jan 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–74.
doi:
10.1016/0378-1119(94)90802-8.
PMID8125298.
Andersson B, Wentland MA, Ricafrente JY, Liu W, Gibbs RA (Apr 1996). "A "double adaptor" method for improved shotgun library construction". Analytical Biochemistry. 236 (1): 107–13.
doi:
10.1006/abio.1996.0138.
PMID8619474.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (Oct 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56.
doi:
10.1016/S0378-1119(97)00411-3.
PMID9373149.
Frye RA (Jul 2000). "Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins". Biochemical and Biophysical Research Communications. 273 (2): 793–98.
doi:
10.1006/bbrc.2000.3000.
PMID10873683.
De Smet C, Nishimori H, Furnari FB, Bögler O, Huang HJ, Cavenee WK (May 2002). "A novel seven transmembrane receptor induced during the early steps of astrocyte differentiation identified by differential expression". Journal of Neurochemistry. 81 (3): 575–88.
doi:
10.1046/j.1471-4159.2002.00847.x.
PMID12065666.
S2CID23925334.